United States. Securities and Exchange Commission
Lineage Cell Therapeutics, Inc., a biotechnology company, has filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC) on November 9, 2023. According to the filing, the company submitted 14 documents, including reports of material events and corporate changes. This filing is a mandatory disclosure requirement for
United States. Securities and Exchange Commission
Biotech giant Amgen Inc. filed a document with the U.S. Securities and Exchange Commission (SEC) on November 7, 2023, revealing detailed information about the company's ownership and equity securities. As a publicly traded company, Amgen Inc. is required to submit regular reports to the SEC, providing transparency
United States. Securities and Exchange Commission
CEL-SCI Corporation, a Phase 3 cancer immunotherapy company, has successfully closed a public offering of 2,490,000 shares of its common stock. The offering was priced at $2.00 per share, generating approximately $5 million in gross proceeds before deducting underwriting discounts and offering expenses. The company intends to
United States. Securities and Exchange Commission
EchoStar Corporation has filed a Form 8-K with the U.S. Securities and Exchange Commission announcing the appointment of Hamid Akhavan, the current Chief Executive Officer and President of EchoStar, as the new President and Chief Executive Officer of DISH Network Corporation, effective November 13, 2023. This move follows the
United States. Securities and Exchange Commission
Neurocrine Biosciences, Inc., a Delaware-based biopharmaceutical company, has resolved patent litigation with Lupin Limited, a global pharmaceutical company, regarding its medication Ingrenza (KV vs. INGREZZA), used to treat tardive dyskinesia and chorea associated with Huntington's disease. The settlement, announced on November 9, 2023, allows Lupin to sell generic
Information technology services industry
Kratos Defense & Security Solutions, a leading technology company in the defense, national security, and global markets, has announced the retirement of two directors and the appointment of two new directors to its board of directors. The retirees, Samuel Liberatore and Jane Judd, have been part of the board since
Cybernet Data Systems Inc.
Energy Transfer LP, a leading energy company, and Crestwood Equity Partners LP, a midstream master limited partnership, announced on November 1, 2023, the preliminary results of the election made by holders of Crestwood's outstanding 9.250% Perpetual Preferred Units regarding the form of merger consideration to be received
Cybernet Data Systems Inc.
Apollo Global Management, Inc. has reported financial results for the third quarter ended September 30, 2023. The company's CEO, Marc Rowan, stated that despite challenging market conditions, Apollo's business model has demonstrated resilience and growth characteristics. Apollo's leading Asset Management and Retirement Services franchises
Information technology services industry
Ryder System, Inc. has filed a registration statement with the Securities and Exchange Commission for the offering and sale of $400,000,000 aggregate principal amount of 6.300% Notes due 2028 and $600,000,000 aggregate principal amount of 6.600% Notes due 2033. The Company has elected to
United States. Securities and Exchange Commission
Elevance Health's affiliated health plans have seen a significant drop in their Medicare Advantage Star Ratings, with the percentage of members in 4-star or higher-rated plans expected to decline to approximately 34% as of 2024, compared to 64% in 2023. This decline is primarily driven by three large
United States. Securities and Exchange Commission
Centene Corporation, a healthcare company operating in the United States, has filed a Form 8-K report with the U.S. Securities and Exchange Commission disclosing the company's performance in the 2024 Medicare Advantage Star Ratings issued by the Centers for Medicare and Medicaid Services. According to the report,
United States. Securities and Exchange Commission
Comera Life Sciences Holdings, Inc., a Delaware-based biotech company, has filed a current report (FORM 8-K) with the U.S. Securities and Exchange Commission (SEC) on October 2, 2023. The report provides details on the company's recent activities, including a private placement of common stock and warrants, and
